Yu W-D, Sun G, Li J, Xu J, Wang X (2019) Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett 452:66–70

Article  PubMed  Google Scholar 

Guo L, Zhang H, Chen B (2017) Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 8(3):410

Article  PubMed  PubMed Central  Google Scholar 

Camacho LH (2015) CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med 4(5):661–672

Article  PubMed  PubMed Central  Google Scholar 

Govindan R, Aggarwal C, Antonia SJ et al (2022) Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer 10(5):e003956

Article  PubMed  PubMed Central  Google Scholar 

Hendriks L, Kerr K, Menis J et al (2023) Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆. Ann Oncol 34(4):358–376

Article  PubMed  Google Scholar 

Ready NE, Ott PA, Hellmann MD et al (2020) Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol 15(3):426–435

Article  PubMed  Google Scholar 

Antonia SJ, López-Martin JA, Bendell J et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:372

Google Scholar 

Gotschall T (2021) EndNote 20 desktop version. J Med Lib Assoc : JMLA 109(3):520

Google Scholar 

Johnson N, Phillips M (2018) Rayyan for systematic reviews. J Electron Resour Librariansh 30(1):46–48

Article  Google Scholar 

Marin F, Rohatgi A, Charlot S (2017) WebPlotDigitizer, a polyvalent and free software to extract spectra from old astronomical publications: application to ultraviolet spectropolarimetry. arXiv preprint arXiv:1708.02025

Chen AP, Setser A, Anadkat MJ et al (2012) Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol 67(5):1025–39

Article  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928 https://doi.org/10.1136/bmj.d5928[published Online First: Epub Date]|.

Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of clinical epidemiology 2011;64(4):401–06

Schwarzer G (2007) meta: An R package for meta-analysis. R news 7(3):40–45

Google Scholar 

DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105–114

Article  PubMed  Google Scholar 

Owonikoko TK, Park K, Govindan R et al (2021) Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol 39(12):1349–1359

Article  PubMed  PubMed Central  Google Scholar 

Lai GG, Yeo JC, Jain A et al (2022) A randomized phase 2 trial of nivolumab versus nivolumab-ipilimumab combination in EGFR-mutant NSCLC. JTO Clin Res Rep 3(12):100416

PubMed  PubMed Central  Google Scholar 

Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med 381(21):2020–2031

Article  PubMed  Google Scholar 

Gettinger SN, Redman MW, Bazhenova L et al (2021) Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the lung-MAP S1400I phase 3 randomized clinical trial. JAMA Oncol 7(9):1368–1377

Article  PubMed  PubMed Central  Google Scholar 

Cascone T, Leung CH, Weissferdt A et al (2023) Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593–604

Article  PubMed  PubMed Central  Google Scholar 

Chen J, Li S, Yao Q et al (2020) The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol 18:1–11

Article  Google Scholar 

Yang Y, Jin G, Pang Y et al (2020) Comparative efficacy and safety of nivolumab and nivolumab plus ipilimumab in advanced cancer: a systematic review and meta-analysis. Front Pharmacol 11:40

Article  PubMed  PubMed Central  Google Scholar 

Serritella AV, Shenoy NK (2023) Nivolumab plus ipilimumab vs nivolumab alone in advanced cancers other than melanoma: a meta-analysis. JAMA Oncol 9(10):1441–1446

Article  PubMed  PubMed Central  Google Scholar 

Dingemans A-M, Früh M, Ardizzoni A et al (2021) Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 32(7):839–853

Article  PubMed  Google Scholar 

Squibb B-M. Opdivo (nivolumab) prescribing information. Bristol-Myers Squibb: Princeton, NJ, USA 2020

Spigel D, Vicente D, Ciuleanu T et al (2021) Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆. Ann Oncol 32(5):631–641

Article  PubMed  Google Scholar